Sodium Bicarbonate for Health & Longevity - Quick Reference Sheet

Sodium Bicarbonate for Health & Longevity

Created on 06/27/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

A cheap alkaline salt with one clearly supported use: buffering acid buildup during hard, intense exercise lasting roughly half a minute to twelve minutes. It may slow kidney decline in failing kidneys, though the largest trial found no benefit. Main drawbacks are stomach upset and a heavy salt load. (Full Review)

Protocol

Ergogenic Dose
0.2–0.3 g/kg
0.3 g/kg optimal (~21 g for 70 kg), 60–180 min before exercise
Multi-Day Loading
0.4–0.5 g/kg/day
Split into smaller doses at meals for 3–7 days before the event
Kidney Disease
~500 mg 3×/day
Titrated upward to bring serum bicarbonate into target range
Time to effect
Exercise Performance
60–180 min
Acute; blood bicarbonate peaks, no buildup period needed
Acidosis Correction
Days–weeks
Serum bicarbonate normalizes in chronic kidney disease
Kidney Benefits
Months
Functional or structural benefits emerge where they occur

Benefits

Contraindications
  • Metabolic or respiratory alkalosis
  • Severe edema
  • Decompensated heart failure (NYHA Class III–IV)
  • Uncontrolled hypertension (systolic ≥160 mmHg)
  • Strict sodium restriction
  • Advanced kidney disease (eGFR <30 mL/min/1.73 m²)
Key Interactions
  • Certain antibiotics (tetracyclines, fluoroquinolones, ketoconazole)
  • Iron and zinc supplements
  • Weakly acidic drugs (aspirin/salicylates, lithium)
  • Weakly basic drugs (amphetamines, ephedrine, quinidine)
  • Other antacids and sodium- or calcium-containing products
  • Calcium supplements
  • Alkalizing agents (potassium citrate, calcium carbonate)
  • Diuretics (loop, thiazide)
  • Corticosteroids

Risk & Side Effects

  • High: Gastrointestinal distress; high sodium load
  • Medium: Blood pressure elevation; fluid retention and edema
  • Low: Metabolic alkalosis; hypokalemia and electrolyte shifts
  • Speculative: Milk-alkali syndrome; stomach rupture from acute overdose

Monitoring

Marker Target Why
Serum Bicarbonate (CO2) 23–27 mmol/L Tracks acid-base correction and avoids over-alkalinization
Serum Potassium 4.0–4.5 mmol/L Detects alkalosis-driven shifts and diuretic interactions
Serum Sodium 135–142 mmol/L Monitors sodium load and fluid balance
eGFR >60 mL/min/1.73 m² (or stable for CKD) Tracks kidney function, the key determinant of safety and benefit
Blood Pressure <120/80 mmHg Detects sodium-driven elevation
Urine pH (if for stones) 6.5–7.0 Confirms adequate urinary alkalinization

Cadence: For therapeutic kidney use, at 1–4 weeks after starting or dose change, then every 3–6 months once stable; routine lab monitoring generally unnecessary for athletic use.

Qualitative Assessment

  • Exercise performance and perceived exertion during high-intensity efforts
  • Gastrointestinal tolerance (bloating, nausea) after dosing
  • Energy and recovery between sessions
  • Signs of fluid retention (ankle swelling, rapid weight gain)
  • In kidney use, nutritional status and muscle mass over time